Wire open Last filed Lilly Hims deal puts Zepbound and Foundayo on telehealth at self pay prices RSS
Peptide Zone

Peptide medicine news,
filed as it happens.

Morning wire

Peptide medicine news filed as it happens

Peptide Zone is a news wire for peptide medicines such as GLP-1 drugs, amylin analogues and peptide vaccines. Each story covers one regulator decision, trial readout, industry deal or safety review, names its primary source and says what comes next. Nothing here is medical advice. About the newsroom

UrgentINDNews

Lilly Hims deal puts Zepbound and Foundayo on telehealth at self pay prices

Eli Lilly will offer Zepbound and Foundayo through Hims & Hers at its standard self pay prices, eight months after Hims moved away from compounded GLP 1 drugs. Financial terms, timing and patient numbers were not disclosed.

INDIANAPOLIS

$149Starting monthly self pay price for Foundayo on the Hims & Hers platform, according to Lilly
  1. What's newEli Lilly and Hims & Hers announced an agreement that lets eligible patients prescribed on the Hims & Hers platform get Zepbound and Foundayo at Lilly's self pay prices.
  2. Why it mattersHims & Hers once built its weight loss business on compounded GLP 1 drugs, and both leading GLP 1 makers now have branded medicines on its platform. The deal adds a sales route without lowering prices.
  3. What's nextThe companies gave no start date, terms or patient targets. Later quarterly reports from Lilly and Hims & Hers may show whether the channel moves Foundayo and Zepbound volume.

Latest on the wire

Full wire

The 60-second briefing

Five things filed most recently

  1. SAF · 6 Nov 2026The Daily Mail reported patient accounts and published case reports of allodynia, skin that hurts at a light touch, in people taking semaglutide or tirzepatide. Several patients improved after a dose cut or a pause.
  2. REG · 6 Nov 2026A pharmacist's analysis says the interim HHS policy for six compounded peptides cites human studies and a test certificate for BPC 157 without naming or publishing them.
  3. SAF · 6 Nov 2026A Straight Arrow News report on November 5 gathered evidence on hair loss, nail changes and NAION vision loss with GLP 1 drugs, including a Rutgers led claims study and new nail research.
  4. IND · 6 Nov 2026Kimberly-Clark CEO Mike Hsu told analysts Rogaine sales are up 30% year to date and said the rise may be driven by some GLP 1 adoption.
  5. TRL · 5 Nov 2026Camurus dosed the first patient in LUNAR-2, a placebo-controlled Phase 2b trial of its monthly semaglutide depot CAM2056 in 150 adults with obesity or overweight.

By the numbers

The one figure each story turns on.

20.9% vs 9.4%Average weight loss at 80 weeks on the higher retatrutide dose versus Ozempic, per Lilly TRL · 28 OCT · Retatrutide Ozempic trial shows bigger A1C drop and double the weight loss 28.7%average weight loss on the highest dose after 68 weeks TRL · 11 DEC · Retatrutide posts the largest average weight loss yet in a phase 3 trial 62.9%of treated patients saw liver inflammation resolve without fibrosis worsening, vs 34.3% on placebo REG · 15 AUG · Wegovy gets accelerated approval for fatty liver disease with scarring 20.2%average weight loss on tirzepatide vs 13.7% on semaglutide after 72 weeks TRL · 11 MAY · Tirzepatide beats semaglutide on weight loss head to head 1stprescription drug approved to treat obstructive sleep apnea in adults with obesity REG · 20 DEC · FDA clears tirzepatide as the first medicine for obstructive sleep apnea ~80%Wegovy pill share of new to brand US prescriptions in Q3 2026, as reported by Novo Nordisk IND · 05 NOV · Wegovy pill market share holds near 80 percent as Novo raises outlook

Threads we are following

Storylines that span months. Each dot is a story, placed by date.

Thread · 4 stories

Compounded copies and the rules around them

What can people legally get, and how do regulators react when demand outruns supply?

Dec 2024Nov 2026

  • 21 MARSemaglutide copies arrive as key patents lapse outside the US and Europe
  • 06 JUNEU safety committee adds a rare eye condition to semaglutide warnings

Thread · 6 stories

The incretin race

Who ends up with the most weight loss, the fewest side effects and the easiest dosing?

Dec 2024Nov 2026

  • 22 DECThe first GLP 1 pill for weight management gets the green light
  • 07 AUGThe weight loss pill that is not a peptide posts its first obesity readout

Thread · 4 stories

Beyond the scale

Which organ benefits hold up in outcome trials, and which do not?

Dec 2024Nov 2026

  • 24 NOVWhy semaglutide failed to slow Alzheimer's in the EVOKE trials
  • 28 JANSemaglutide wins a kidney label after the FLOW outcome trial

Desk fronts

REGRegulators12
TRLTrials25
INDIndustry17
SAFSafety25
EXPExplainers4

Where this news came from

Primary source type of every story on the wire. How we label sources

  • Regulator15
  • Journal10
  • Company release22
  • Conference8
  • Our newsroom28